Sign In

Peter J. Houghton PhD

Peter J. Houghton PhD
ProfessorCollege of MedicinePeter.Houghton@nationwidechildrens.org
Children's Hospital 700 Children's Drive Columbus OH 43205
Phone:614-355-2670Fax:
  • Experimental Therapeutics
  • Pediatric Oncology (Developing)

Current Publications

  • Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R, Keir ST, Maris JM, Billups CA, Desjardins C, Kurmasheva RT, Houghton PJ, Smith MAInitial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program.Pediatr Blood Cancer 60(8) 1325-32 8/1/2013
  • Lock RB, Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Billups CA, Kurmasheva RT, Houghton PJ, Smith MAInitial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program.Pediatr Blood Cancer 60(7) E42-5 7/1/2013
  • Shen C, Oswald D, Phelps D, Cam H, Pelloski CE, Pang Q, Houghton PJRegulation of FANCD2 by the mTOR Pathway Contributes to the Resistance of Cancer Cells to DNA Double-Strand Breaks.Cancer Res 73(11) 3393-401 6/1/2013
  • Bid HK, London CA, Gao J, Zhong H, Hollingsworth RE, Fernandez S, Mo X, Houghton PJDual Targeting of the Type 1 Insulin-like Growth Factor Receptor and Its Ligands as an Effective Antiangiogenic Strategy.Clin Cancer Res 19(11) 2984-94 6/1/2013
  • Smith MA, Houghton PJA proposal regarding reporting of in vitro testing results.Clin Cancer Res 19(11) 2828-33 6/1/2013
  • Keir ST, Maris JM, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MAInitial testing (stage 1) of temozolomide by the pediatric preclinical testing program.Pediatr Blood Cancer 60(5) 783-90 5/1/2013
  • Reynolds CP, Kang MH, Carol H, Lock R, Gorlick R, Kolb EA, Kurmasheva RT, Keir ST, Maris JM, Billups CA, Houghton PJ, Smith MAInitial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.Pediatr Blood Cancer 60(5) 791-8 5/1/2013
  • Carol H, Reynolds CP, Kang MH, Keir ST, Maris JM, Gorlick R, Kolb EA, Billups CA, Geier B, Kurmasheva RT, Houghton PJ, Smith MA, Lock RBInitial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 60(4) 633-41 4/1/2013
  • Carol H, Szymanska B, Evans K, Boehm I, Houghton PJ, Smith MA, Lock RBThe anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.Clin Cancer Res 19(7) 1795-805 4/1/2013
  • Kaplon R, Hadziahmetovic M, Sommerfeld J, Bondra K, Lu L, Leasure J, Nguyen P, McHugh K, Li N, Chronowski C, Sebastian N, Singh M, Kurmasheva R, Houghton P, Pelloski CEThe application of radiation therapy to the Pediatric Preclinical Testing Program (PPTP): results of a pilot study in rhabdomyosarcoma.Pediatr Blood Cancer 60(3) 377-82 3/1/2013
  • Gorlick R, Kolb EA, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MAInitial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.Pediatr Blood Cancer 59(7) 1266-74 12/15/2012
  • Smith MA, Kang MH, Reynolds CP, Kurmasheva RT, Alexander D, Billups CA, Toretsky JA, Houghton PJEvaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.Pediatr Blood Cancer 59(4) 753-5 10/1/2012
  • Batra V, Maris JM, Kang MH, Reynolds CP, Houghton PJ, Alexander D, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Billups CA, Smith MAInitial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.Pediatr Blood Cancer 59(4) 749-52 10/1/2012
  • Gorlick R, Maris JM, Houghton PJ, Lock R, Carol H, Kurmasheva RT, Kolb EA, Keir ST, Reynolds CP, Kang MH, Billups CA, Smith MATesting of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 59(3) 518-24 9/1/2012
  • Keir ST, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MAInitial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 59(3) 586-8 9/1/2012
  • Smith MA, Gorlick R, Kolb EA, Lock R, Carol H, Maris JM, Keir ST, Morton CL, Reynolds CP, Kang MH, Arts J, Bashir T, Janicot M, Kurmasheva RT, Houghton PJInitial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.Pediatr Blood Cancer 59(2) 329-32 8/1/2012
  • Smith MA, Gorlick R, Kolb EA, Lock R, Carol H, Maris JM, Keir ST, Morton CL, Reynolds CP, Kang MH, Arts J, Bashir T, Janicot M, Kurmasheva RT, Houghton PJInitial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.Pediatr Blood Cancer 59(2) 329-32 8/1/2012
  • Smith MA, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Morton CL, Wu J, Smith PG, Yu J, Houghton PJInitial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.Pediatr Blood Cancer 59(2) 246-53 8/1/2012
  • Furman WL, McGregor LM, McCarville MB, Onciu M, Davidoff AM, Kovach S, Hawkins D, McPherson V, Houghton PJ, Billups CA, Wu J, Stewart CF, Santana VMA single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.Invest New Drugs 30(4) 1660-70 8/1/2012
  • Kang MH, Reynolds CP, Houghton PJ, Alexander D, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Wozniak A, Smith MAInitial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.Pediatr Blood Cancer 59(1) 185-8 7/15/2012
  • Lock RB, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gorlick R, Kolb EA, Houghton PJ, Smith MAInitial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program.Pediatr Blood Cancer 58(6) 916-23 6/1/2012
  • Kolb EA, Gorlick R, Maris JM, Keir ST, Morton CL, Wu J, Wozniak AW, Smith MA, Houghton PJCombination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program.Pediatr Blood Cancer 58(5) 729-35 5/1/2012
  • Kolb EA, Gorlick R, Keir ST, Maris JM, Lock R, Carol H, Kurmasheva RT, Reynolds CP, Kang MH, Wu J, Houghton PJ, Smith MAInitial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.Pediatr Blood Cancer 58(5) 815-8 5/1/2012
  • Houghton PJ, Kang MH, Reynolds CP, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Billups CA, Smith MAInitial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 58(4) 636-9 4/1/2012
  • Morton CL, Maris JM, Keir ST, Gorlick R, Kolb EA, Billups CA, Wu J, Smith MA, Houghton PJCombination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.Pediatr Blood Cancer 58(4) 566-71 4/1/2012
  • McGregor LM, Stewart CF, Crews KR, Tagen M, Wozniak A, Wu J, McCarville MB, Navid F, Santana VM, Houghton PJ, Furman WL, Galindo CRDose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors.Pediatr Blood Cancer 58(3) 372-9 3/1/2012
  • Bid HK, Zhan J, Phelps DA, Kurmasheva RT, Houghton PJPotent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2.Mol Cancer Ther 11(3) 649-59 3/1/2012
  • Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Phelps D, Maris JM, Billups C, Smith MAInitial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program.Pediatr Blood Cancer 58(2) 191-9 2/1/2012
  • Houghton PJ, Lock R, Carol H, Morton CL, Gorlick R, Anders Kolb E, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups CA, Zhang MX, Madden SL, Teicher BA, Smith MATesting of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.Pediatr Blood Cancer 58(2) 200-9 2/1/2012
  • Bid HK, Oswald D, Li C, London CA, Lin J, Houghton PJAnti-angiogenic activity of a small molecule STAT3 inhibitor LLL12.PLoS One 7(4) e35513 1/1/2012
  • Sugahara K, Thimmaiah KN, Bid HK, Houghton PJ, Rangappa KSAnti-tumor activity of a novel HS-mimetic-vascular endothelial growth factor binding small molecule.PLoS One 7(8) e39444 1/1/2012
  • Sugahara K, Thimmaiah KN, Bid HK, Houghton PJ, Rangappa KSCorrection: Anti-Tumor Activity of a Novel HS-Mimetic-Vascular Endothelial Growth Factor Binding Small Molecule.PLoS One 7(10) 1/1/2012
  • Fleuren ED, Versleijen-Jonkers YM, van de Luijtgaarden AC, Molkenboer-Kuenen JD, Heskamp S, Roeffen MH, van Laarhoven HW, Houghton PJ, Oyen WJ, Boerman OC, van der Graaf WTPredicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507.Clin Cancer Res 17(24) 7693-703 12/15/2011
  • Carol H, Boehm I, Reynolds CP, Kang MH, Maris JM, Morton CL, Gorlick R, Kolb EA, Keir ST, Wu J, Wozniak AE, Yang Y, Manfredi M, Ecsedy J, Wang J, Neale G, Houghton PJ, Smith MA, Lock RBEfficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.Cancer Chemother Pharmacol 68(5) 1291-304 11/1/2011
  • Reynolds CP, Kang MH, Keir ST, Gorlick R, Kolb EA, Lock R, Maris JM, Carol H, Morton CL, Billups CA, Smith MA, Houghton PJInitial testing of lenalidomide by the pediatric preclinical testing program.Pediatr Blood Cancer 57(4) 606-11 10/1/2011
  • Katsumi Y, Iehara T, Miyachi M, Yagyu S, Tsubai-Shimizu S, Kikuchi K, Tamura S, Kuwahara Y, Tsuchiya K, Kuroda H, Sugimoto T, Houghton PJ, Hosoi HSensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.Biochem Biophys Res Commun 413(1) 62-8 9/16/2011
  • Houghton PJ, Lock R, Carol H, Morton CL, Phelps D, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gu Y, Wilson WR, Smith MAInitial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.Pediatr Blood Cancer 57(3) 443-53 9/1/2011
  • Smith MA, Maris JM, Lock R, Kolb EA, Gorlick R, Keir ST, Carol H, Morton CL, Reynolds CP, Kang MH, Houghton PJInitial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.Pediatr Blood Cancer 57(2) 268-74 8/1/2011
  • Bhagwat SV, Gokhale PC, Crew AP, Cooke A, Yao Y, Mantis C, Kahler J, Workman J, Bittner M, Dudkin L, Epstein DM, Gibson NW, Wild R, Arnold LD, Houghton PJ, Pachter JAPreclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.Mol Cancer Ther 10(8) 1394-406 8/1/2011